A multi-centre, double-blind, randomised, placebo-controlled trial using CD133 enriched bone marrow cells following primary angioplasty for acute myocardial infarction with central core laboratory analysis.
Phase 2
Withdrawn
- Conditions
- 1001928010007593heart failureischemic cardiomyopathy
- Registration Number
- NL-OMON36752
- Lead Sponsor
- Cardiovascular Center Aalst
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Withdrawn
- Sex
- Not specified
- Target Recruitment
- 30
Inclusion Criteria
conform nederlandse tekst
Exclusion Criteria
conform nederlandse tekst
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>conform nederlandse tekst</p><br>
- Secondary Outcome Measures
Name Time Method <p>conform nederlandse tekst</p><br>